Fin Trust Capital Advisors, LLC Halozyme Therapeutics, Inc. Transaction History
Fin Trust Capital Advisors, LLC
- $577 Million
- Q3 2024
A detailed history of Fin Trust Capital Advisors, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Fin Trust Capital Advisors, LLC holds 132 shares of HALO stock, worth $7,683. This represents 0.0% of its overall portfolio holdings.
Number of Shares
132
Previous 132
-0.0%
Holding current value
$7,683
Previous $6,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
559Shares Held
124MCall Options Held
668KPut Options Held
259K-
Black Rock Inc. New York, NY17.6MShares$1.03 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$773 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$418 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.17MShares$243 Million4.34% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$201 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.11B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...